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INTRODUCTION
Vulvovaginitis is the one of the most common 
gynaecological condition seen in women worldwide. 
The three common vaginal infections include 
vulvovaginal candidiasis (VVC), bacterial vaginosis, 
and Trichomonas vaginalis infection; there is a paucity 
of data on the global and national burden of these 
infections. 
 Vulvovaginal candidiasis frequently results 
from an overgrowth of the normal flora Candida 
species in the vagina. Candida is usually present 
in the lower female genital tract in small amounts, 
being part of the normal flora in 10-20% of healthy 
asymptomatic women (1). The over growth of the 
yeast and development of vulvovaginitis is usually 
prevented by the balance created by bacteria such as 
Lactobacillus acidophilus. Any condition that disrupts 
this balance of the normal flora predisposes to VVC. 
These include antibiotic use, oral contraceptives and 
contraceptive devices, high oestrogen levels and 
immunocompromised states such as diabetes mellitus 
and HIV. 
 C. albicans is responsible for most cases of VVC 
(2, 3); the rest are caused by non-albican species 
of Candida which include C. glabrata, C. krusei, 
and C. tropicalis. Non-albican species of Candida 
have demonstrated decreased susceptibility to 
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ABSTRACT
Objectives: To identify yeast isolates in vaginal specimens to species level and determine 
their antifungal susceptibility patterns.
Design: Cross-sectional laboratory-based study.
Setting: The Aga Khan University Hospital (AKUH), Nairobi.
Subjects: Yeast isolates from high vaginal swabs presented to the laboratory for culture 
and sensitivity were identified to species level using the API Candida system and 
subjected to broth microdilution susceptibility testing.
Main outcome measures: Frequency tables and graphs were used to summarise the data. 
Susceptibility data was analysed by the non-parametric Fisher’s exact test. P<0.05 was 
considered statistically significant. 
Results: A total of 101 yeasts were studied. C.albicans was the prominent species (69.3%) 
followed by C. glabrata (12.9%), C. famata (5.0%), C. krusei (3.0%), Trichosporon species 
(3.0%) and S.cerevisiae (3.0%), C.parapsilosis (1.0%). Three (3.0%) of the isolates had 
profiles that fell between C. glabrata and C. famata. The percentages of C. albicans 
susceptible to flucytosine, amphotericin B, fluconazole and itraconazole were 94.3, 
92.9, 100 and 90 respectively; that of non-albicans isolates were 93.5, 80.6, 77.4 and 29 
respectively. There was no significant difference (p>0.05) between the susceptibility 
of C.albicans and non-albicans isolates to flucytosine and amphotericin B, however 
there was a significant difference (p<0.05) to fluconazole and itraconazole. 
Conclusions: C. albicans was the predominant cause of vulvovaginal candidiasis 
in this study, and demonstrated good susceptibility to antifungal agents tested. A 
significant number of non-albicans yeasts were identified; these demonstrated reduced 
susceptibility to all drugs, in particular to the azoles which are commonly used for 
treatment of vaginal candidiasis. The isolation of non-albicans yeasts may have clinical 
implication given their reduced susceptibility to antifungals. 
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commonly used antifungal agents (5). C.krusei has 
intrinsic resistance while C. glabrata has decreased 
susceptibility to fluconazole. C. albicans has also been 
shown to be developing resistance to the azole group 
of antifungal agents. This makes identification of 
yeasts to species level and antifungal susceptibility 
testing necessary in order to appropriately select the 
agent to use. Antifungal susceptibility testing may 
be used to predict clinical response, or at least to 
forecast treatment failure, and consequently can be 
used to develop local antibiograms to aid in empirical 
selection of antifungals; in testing of isolates to aid 
in selection of long-term therapy, and in testing of 
isolates from recurrent mucosal disease to aid in 
selection of alternative regimens. 
 Species identification and antifungal drug 
sensitivity profiles are not routinely carried out in 
the management of vaginal discharge among women 
seeking medical care in health facilities in Kenya. 
Therefore the present species distribution patterns 
and status of fungal resistance to conventional 
antifungal drugs among women in Kenya is largely 
unknown. This cross-sectional laboratory-based 
study was therefore designed to determine the species 
of yeasts causing vaginal infection and the current 
antifungal susceptibility patterns in the study set up. 
Documentation of a significant level of non-albicans 
species of Candida and their susceptibility patterns 
would pave the way for larger studies that would 
inform on any policy changes required in the of 
vaginal candidiasis. 
MATERIALS AND METHODS
Study area: The study was carried out at the 
Microbiology laboratory of the Aga Khan University 
Hospital, a private university-affiliated hospital in 
Nairobi. The laboratory is well equipped and receives 
laboratory specimens from inpatients, outpatients 
from the casualty and outpatient clinics, as well as 
patients seeking medical care from the private doctors’ 
clinics in the private wing. 
Study population: All vaginal yeasts isolated at the 
Microbiology laboratory during the study period. 
Sample size: The minimum desired number of samples 
to be analysed was 100.
Sampling: Consecutive sampling was used to select 
the vaginal yeasts for processing. 
Inclusion criteria: Yeasts that demonstrated moderate 
or heavy growth on Sabouraud dextrose agar (SDA) 
were included in the study. In those with light 
growth, the gram stain from the original specimen 
was examined and only those with pus cells >2+ were 
included in the study. 
Laboratory procedures: Suspected yeast colonies were 
examined in a drop of normal saline for budding 
cells, and confirmed by the Gram stain. The yeast 
isolates were identified to species level using API® 
Candida system (BioMerieux, Marcy-l ‘Etoile, 
France). The API Candida strip consists of ten tubes 
containing dehydrated substrates, which enabled 
the performance of sugar acidification tests and 
enzymatic reactions. The reactions produced during 
incubation were revealed by spontaneous color 
changes which were transformed into a numerical 
profile using the interpretation table provided. The 
numerical profile obtained was compared to those 
given in the profile list in the package insert to get 
the yeast species. 
 The susceptibility of the 101 yeast isolates to four 
antimycotics was tested using the broth microdilution 
method using ATB® Fungus 2INT (BioMerieux, Marcy-
I’Etoile, France). The kit contains the following drug 
dilution ranges: amphotericin B (AMB) 0.5-16mgl-1, 
5-flucytosine (5FC) 0.5-64 mgl-1, fluconazole (FCA) 
0.25-128 mgl-1 and itraconazole (ITR) 0.125-4 mgl-1. 
The strip consists of 16 pairs of cupules. The first pair 
does not contain any antifungal agent and is used as 
a positive growth control. The next 15 pairs contain 
the four antifungal agents at several concentrations, 
enabling minimum inhibitory concentration (MIC) 
determination. The preparation of the inoculums, strip 
inoculation and incubation, and reading of the results 
were carried out according to the manufacturer’s 
instructions. The growth score was read for each 
cupule and the MIC determined for each drug as per 
instructions. The MICs were interpreted into clinical 
guidelines, sensitive, intermediate and resistant, by 
using Clinical and Laboratory Standards Institute (CLSI) 
recommended breakpoints (in µgml-1) for Candida 
species, provided in the manufacturer’s instructions. 
Data management: All data collected from the 
laboratory procedures were entered into MS Excel, 
verified and cleaned. Statistical analysis was 
performed using Statistical Package for Social Sciences 
(SPSS) for Windows, version 12.0 (SPSS Inc., Chicago, 
IL, USA). Frequency tables and graphs were used 
to summarize the data. The susceptibility data was 
analyzed by the non-parametric Fisher’s exact test. 
P< 0.05 was considered statistically significant. 
RESULTS
Species identification and distribution: A total of 101 yeast 
isolates were collected and tested between November 
2006 and January 2007 (Table 1). Candida species 
accounted for 94.1 % of the isolates with C.albicans 
being the most common (73.7% of all Candida species) 
(Figure 1). Among the non-albicans species, C.glabrata 
(13.7% of all Candida species) and C.famata (5.3%) 
were the most commonly identified species. Three of 
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the non-albicans isolates had profiles that fell between 
C. glabrata and C. famata. Six isolates were identified 
as non-Candida yeasts (Figure 2). 
Table 1
Species distribution of vaginal yeasts isolated from 
women with vaginal discharge at the AKUH 
Specie Isolates   
 No. (%)  
C.albicans 70  69.3   
C.glabrata 13  12.9   
C.famata 5    5.0   
C.krusei 3    3.0  
C.parapsilosis 1    1.0   
Unidentified Candida species* 3    3.0   
Trichosporon species 3    3.0
Saccharomyces cerevisia 3    3.0
*Numerical profile could not differentiate 
between C.glabrata and C.famata 
Figure 1
Percentage distribution of Candida species isolated from 
women with vaginal discharge at the AKUH
** Numerical profiles could not differentiate between 
C. glabrata and C. famata
Figure 2
Percentage distribution of yeast species isolated from 
women with vaginal discharge at the AKUH
* C. glabrata, C. Famata, C. krusei, C. Parapsilosis, 
unidentified Candida species (C.glabrata/ C.famata)
** Trichosporon species, S. cerevisiae
Antifungal susceptibility testing: The 101 isolates were 
tested for susceptibility to flucytosine, amphotericin 
B, fluconazole and itraconazole. Overall, 55 of the 70 
C. albicans (78.6%), six of the 25 non-albicans Candida 
strains (24%) and one of the six strains of non-candidal 
yeasts (16.7%) were susceptible to all tested antifungal 
agents. Resistance to one drug was demonstrated 
by 20% of the C. albicans strains (amphotericin B or 
fluconazole or itraconazole), 52% of the non-albicans 
Candida (flucytosine or itraconazole) and 66.7% of the 
non-candidal yeasts (amphotericin B or itraconazole). 
Of the C. albicans strains, 1.4% showed resistance to two 
of the tested agents (amphotericin Band itraconazole) 
while 8% of the non-albicans Candida and 16.7% of the 
non-candidal yeasts showed resistance to three of the 
antifungal agents (amphotericin B, fluconazole and 
itraconazole). No isolate tested was resistant to all 
tested antifungal agents. The percentage of resistant 
strains to each of the antifungal agents was as shown 
in Table 2. 
 Ninety five of the 101 yeast isolates (94.1 %) were 
susceptible to flucytosine. One isolate (1.0%) showed 
intermediate susceptibility and five isolates (5.0%) 
were resistant. Sixty six of the 70 C.albicans strains 
(94.3%), 23 of the 25 non-albicans Candida (92%) and 
all the non-candidal yeasts were susceptible. The 
susceptibility patterns to flucytosine did not differ 
significantly between the C. albicans and the other 
yeast isolates (p=0.09) (Table 3). Of the 101 isolates, 
90 (89.1%) were susceptible to amphotericin B and 
11 (10.9%) resistant. Sixty five (92.9%) of C. albicans 
strains, 23 (92%) of the non-albicans Candida and two 
(33.3%) of the non-candidal yeasts were susceptible. 
There was no significant difference between the 
susceptibility patterns of C. albicans and the non-
albican isolates (p=1.00) (Table 3). 
Ninety four of the isolates (93.1%) were 
susceptible to fluconazole. Four isolates (4.0%) were 
susceptible-dose dependent while three (3.0%) were 
resistant. All C. albicans strains were susceptible; 19 
(76%) of the non-albicans Candida and five (83.3%) 
of the non- Candida yeasts were also susceptible. 
One of the three C. krusei strains was susceptible; the 
other two were susceptible-dose dependent. This is 
however not an important finding clinically since 
the species must be considered clinically resistant to 
fluconazole as per CLSI recommendations (6). There 
was significant difference between the susceptibility 
patterns of C. albicans and the other yeast isolates to 
fluconazole (p=0.00) (Table 3). 
 Itraconazole demonstrated the lowest 
susceptibility overall with only 72 of the 101 isolates 
(71.3%) being susceptible, 23 isolates (22.8%) were 
resistant. C.albicans was the species with the highest 
susceptibility at 90%; the lowest was demonstrated by 
C. parapsilosis (0%), C. glabrata (15.4%) and C. famata 
(20%). There was significant difference between the 
susceptibility patterns of C. albicans and the other 
yeast isolates to itraconazole (p=0.00) (Table 3). 
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DISCUSSION
Most (69.3%) of the species isolated in this study 
were C.albicans and a significant percentage (30.7%) 
were non-albicans yeasts (Table 1). The non-albicans 
species isolated were mainly C.glabrata (12.9%) and 
C. famata (5.0%). Only two species of non-candida. 
yeasts were isolated: Trichosporon species and 
S.cerevisiae. C.albicans was the predominant species 
isolated in other studies (7-14) which concurs with 
the findings in this study. The distribution of the 
non-albicans species, however, differed in different 
studies. The most commonly isolated non-albicans 
species differed as C.glabrata (7-13) and C. parapsilosis 
(14). The second most common non-albicans species 
differed in the different studies as C.glabrata (14), 
C. tropicalis (8,10,11) C. parapsilosis (12), C. famata (9) 
and C.krusei (7).
Table 2
In vitro susceptibilities of 101 vaginal yeasts to four antifungal agents as determined by MIC90 
        
               Species
Drug and breakpoint  C. albicans  (0=70) Non-albicans Non- candidal 
   Candida (n=25) yeasts (n=6)   
Flucytosine MIC90 2 4 4   
(MIC >16)
      % resistant 5.7 4  0   
Amphotericin B MIC90 0.5 1 16   
(MIC >2)      % resistant 7.1 8 66.7   
Fluconazole MIC90 1 32 128   
(MIC > 32)     % resistant 0 8 16.7   
Itraconazole MIC90 0.125 4 4   
(MIC > 0.5)     % resistant 10 56 33.3
MIC90 and MIC in µgm-1
Table 3
Antifungal sensitivity patterns of vaginal yeasts isolated from women with
vaginal discharge at the AKUH to amphotericin B, flucytosine, fluconazole and itraconazole 
Variable           Species  Statistical tests   
(Drug) C. albicans Non albicans Fisher Exact test   
AmphotericinB
  Sensitivea 92.9% 80.6% X2= 3.30: 1df   
  ResistantB 7.1%  19.4% P>0.05 (0.09)   
Flucytosine           
  Sensitivec 94.3% 93.5% X2= 0.02: 1df   
  Intermediated & resistant 5.7% 6.5% P>0.05 (1.00)   
Fluconazole           
  Sensitivef 100.0% 77.4% X2= 16.98: 1df   
  S-DDg & resistanth 0.0% 22.6% P<0.05 (0.00)   
   significant   
Itraconazole           
Sensitivei 90.0% 29.0% X2= 39.02: 1df   
S-DDj & ResistantK 10.0% 71.0% P<0.05 (0.00) 
   significant  
S-DD= Susceptible-dose dependent 
aMIC<2µgml-1, bMIC≥2µgml-1, cMIC≤4µgml-1, dMIC=8-16µgml-1, eMIC≥32µgml-1, fMIC≤8µgml-1,
gMIC=16-32µgmr-1, hMIC2≥64µgmr-1, iMIC≤0.125MMI-1 jMIC=0.25-0.5µgml-1, kMIC≥1µgmll
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 Comparing the findings in the current study 
with those of some of the studies which demonstrated 
C.albicans in 40.47-82.90% of isolates, C. glabrata in 
5.6-30.09%, C.famata in 0.08-2.20%, C.krusei in 1.57-
11.17%, C.parapsilosis in 0.49-11.30%, C.tropicalis 
2.43-7.8%, unidentified Candida species in 0.90-7.54%, 
Trichosporon species in 0.29-0.89% and S.cerevisiae in 
0.15-0.70% of isolates. Most of the findings in this 
study were within these ranges except for C.famata, 
Trichosporon species and S. cerevisiae which were more 
frequent in this study. C.tropicalis was also isolated in 
these studies but was not found in the current study 
(7-14). 
 In the current study, flucytosine showed an 
overall susceptibility of 94.1%; 5.0% of the isolates were 
resistant (Table 2). The tested strains demonstrated 
a 0 - 5.7% resistance except for C.krusei which had a 
resistance of 33.3%. The high resistance rate in this 
species may be explained by the low rate of isolation 
of C. krusei (three isolates). Nawrot et al (13) found a 
low frequency (0-3%) of resistance of tested strains 
while Richter et al (12) found an overall resistance 
of 3% with resistance of tested strains in the range 
0-100%. The 100% resistance was found in the strains 
isolated in small numbers in that study (12) C.lusitaniae 
and Trichosporon species which had one isolate each. 
A study on isolates of Cryptococcus neoformans from 
clinical sources from Nairobi found a 21.2% resistance 
to flucytosine (15). This is a drug for treatment of 
cryptococcosis and it has been recommended for use 
in combination with amphotericin B. It was not 
established whether that is actually being done in 
the current study. It was also not established whether 
the patients with flucytosine-resistant isolates had 
previously been on treatment with the drug.
 Amphotericin B, which is the drug of choice for 
cryptococcal meningitis, demonstrated an overall 
susceptibility of 89.1% in this study, with 10.9% of 
isolates being resistant (Table 2). The susceptibility 
testing of this drug is still a controversial area; CLSI 
breakpoints have not yet been defined. Though some 
studies use a breakpoint of 1 µgml-1, strains in this 
study with MIC>2µgml-1 were considered resistant 
according to the manufacturer’s instructions. There is 
limited information on amphotericin B susceptibility 
in this country except for cryptococcal infections. Bii et 
al (15) found a 0% resistance of the drug to C.neoformans 
with a low MIC90 of 0.5µgml-1. In the current study, 
though the resistance was much higher, a similar MIC90 
was found for C.albicans with a resistance of 7.1%; 
the other species had higher MIC90 values Table 2 of 
1 µgml-1 for non-albicans Candida (8% resistant) and 
16µgml-1 for non-candidal yeasts (66.7% resistant). 
Other studies (12,13,16) also demonstrated a low 
frequency of resistance to amphotericin B (0-1%). The 
use of amphotericin B for treatment of cryptococcal 
meningitis, which is an opportunistic infection that 
has increased especially in the wake of the HIV / AIDS 
pandemic, may result in development of resistance in 
the normal flora Candida species found in the vagina 
and in the mouth and if these then cause endogenous 
infection will demonstrate resistance to the drug. The 
resistant strains can also circulate in the community 
and may have far-reaching implications especially 
in the event of systemic candidiasis. 
 Fluconazole demonstrated an overall 
susceptibility of 93.1% and 3.0% resistance in the 
current study (Table 2). Among the isolates in this 
study, C. albicans had a 100% susceptibility which is 
in agreement with the results obtained in the study 
by Pfaller et al (8) that demonstrated C. albicans 
susceptibility of approximately 94-100% though 
with some geographical differences. In the same 
study, the C.albicans isolates from South Africa 
had a susceptibility of 99.4% (0.3% resistant). In 
other studies, C.albicans demonstrated fluconazole 
susceptibility of  11 (84.3%), 13 (92%) and 14 (92.5%). 
C.krusei has intrinsic resistance to fluconazole 
while C. glabrata shows reduced susceptibility. The 
C.glabrata isolates in the current study demonstrated 
a susceptibility of 84.6% (7.7% S-DD, 7.7% resistant). 
The ARTEMIS Global Antifungal Surveillance 
study demonstrated C.glabrata susceptibility in the 
range 29.2-100%; the isolates from S. Africa had a 
susceptibility of 49.6% (21.1% resistant). The MIC90 of 
fluconazole for C.albicans in the current study (Table 
2) was 1 µgml1 (range: 0.25-8) which was similar to 
that obtained by Comert et al (range: 0.125-8) (14). The 
MIC90 for C.glabrata in the current study was 32µgml-1 
(range: 0.25-128) which was much higher than that 
for the same species in the study by Comert et al of 
8µgml-1 (range: 0.125-16). The elevated MIC90 for 
C.glabrata in this study may have been due to either 
the small number of C.glabrata isolates with a wide 
range of MIC distribution or to a rising resistance 
of the isolates in this study. Bii et al in the study on 
C.neoformans demonstrated a resistance to fluconazole 
of 11.2% with a MIC90 of 64µgml-l (15). The MIC90 of 
C.neoformans in that study was higher than that of 
Candida in the current study hence C. neoformans 
demonstrated a higher resistance rate compared to 
Candida. 
 Itraconazole had the lowest overall susceptibility 
(71.3%) in this study with a resistance rate of 22.8% 
(Table 2). C.albicans was the species with the highest 
susceptibility (90%) to this drug with that of the other 
isolates ranging between 0% (for C.parapsilosis which 
had only one isolate) and 100%. The resistance rate 
for C. albicans was 10% which is in agreement with 
that found by Nawrot et al of 11% (13). Non-albicans 
Candida had a resistance rate of 50% in the current 
study which was higher than that found by Galle 
et al of 23.5%. The study by Bii showed itraconazole 
resistance rate of 6.3% (MIC90 0.5µgml-1) which is much 
lower compared to that of Candida isolates in the current 
study. All the isolates resistant to fluconazole were 
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also found to be resistant to itraconazole supporting 
the possibility of cross-resistance between the azoles. 
This cross-resistance may be due to a common mode 
of action of the azole derivatives. 
 Isolates inhibited by fluconazole and itraconazole 
at concentrations of 16-32µgml-1 and 0.25-
0.5µgml-1 respectively are placed in a category 
known as susceptible-dose dependent (S-DD). This 
category identifies yeast isolates with intermediate 
susceptibilities, between fully susceptible and fully 
resistant. Isolates in this category will respond to 
fluconazole if higher doses are administered and 
to itraconazole if higher plasma levels are achieved 
(5). The definition of fluconazole susceptible and 
resistant does not apply for C. krusei since the organism is 
considered to have intrinsic resistance to the drug (6). 
 Identification of yeast isolates to species-level 
may aid in guiding the clinician on therapeutic 
options. VVC may be classified into complicated 
and uncomplicated forms. The uncomplicated form 
is caused by C.albicans, which is usually susceptible 
to all antifungal agents, and responds to short-course 
oral or topical treatment (17). The complicated form is 
recurrent, caused by non-albicans species of Candida 
and requires treatment for >7 days. Patients with 
recurrent VVC are also more likely to acquire resistant 
Candida species due to frequent exposure to antifungal 
agents for the recurrent infections. Approximately 
33% of RVVC is also known to be caused by non-
albicans Candida species some of which are inherently 
less susceptible to common antifungal agents making 
them less useful in their treatment (18). The optimal 
treatment of non-albicans Candida species remains 
unknown1  but they frequently respond to topical boric 
acid or topical flucytosine (17). Isolation of C.krusei 
in any specimen rules out the use of fluconazole for 
the treatment of the patient, even when the isolate 
tests susceptible in-vitro, since the species has intrinsic 
resistance to this antifungal agent while C.glabrata 
shows reduced susceptibility to the same agent, 
C.lusitaniae has been associated with amphotericin B 
resistance. Susceptibility testing is especially useful 
in infections due to non-albicans Candida species 
(17). In the setting of candidemia and deep infections 
susceptibility testing may be of benefit especially in 
cases where initial therapy has failed, the results may 
guide on suitable adjustment of therapy. 
 It is however important for the clinician to 
understand that in-vitro susceptibility results are 
supposed to be guidelines to the treatment of patients 
since they may not always predict the success of a 
particular treatment. However, when the infection 
is caused by a resistant isolate, the tests may predict 
the possibility of failure for a particular agent or 
the dosage. The clinician must also understand 
that in-vivo response to a drug is a combination of 
several factors: drug factors, host factors, site of the 
infection and fungal factors (5). Drug factors include 
the dosage (quantity, frequency and cumulative 
dose), pharmacokinetics (absorption, distribution, 
metabolism and excretion), pharmacodynamics 
and other concomitantly administered drugs 
(drug-drug interactions). Host factors include the 
immune system which works with the drug to clear 
the infection, the site and severity of the infection 
and patient compliance to the given treatment. 
Site of the infection factors include the source of 
the infection, drug penetration and the presence 
of a foreign body which acts as a foci for infection. 
Fungal factors include the species, cell type, the size 
of the micro-organism population, virulence factors, 
evasion of host inflammatory response and biofilm 
formation. All these factors have a role to play in 
the final resolution of the infection and should be 
taken into consideration when starting the patient 
on treatment. 
 The current study had limitations in time and 
cost. Due to these, a small sample size of 101 yeast 
isolates was analyzed. This resulted in some of the 
yeast species being isolated in very small numbers. 
The antifungal susceptibility testing was also to very 
few antifungal agents and none of the new agents in 
the market were tested for example voriconazole. 
 This study therefore paves the way for more 
studies with larger sample sizes, and in different 
parts of the country in order to understand the local 
epidemiology of yeast species and to study the local 
epidemiological susceptibility patterns. These would 
then be used to come up with local antibiograms that 
will aid clinicians in the selection of effective antifungal 
agents that can be used empirically. Larger studies to 
assess the clinical correlation of MIC and outcome 
are also required to enhance the understanding of 
the susceptibility testing in our set up. These studies 
would then form a baseline from which surveillance 
of antifungal drug resistance can be monitored both 
in hospitals and in the community. 
In conclusion, this study observed that C. albicans was 
the prominent cause of vulvovaginal candidiasis in the 
study set up; non-albicans yeasts were a significant 
cause of vulvovaginal candidiasis. C.albicans still 
demonstrates susceptibility to fluconazole and 
itraconazole. There is a higher resistance demonstrated 
by non-albicans yeasts to fluconazole and itraconazole 
than by C.albicans.
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